1. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Issue 6 (June 2022) Authors: Motzer, Robert; Porta, Camillo; Alekseev, Boris; Rha, Sun Young; Choueiri, Toni K; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Kapoor, Anil; Goh, Jeffrey C; Eto, Masatoshi; Bennett, Lee; Wang, Jinyi; Pan, Jie Janice; Saretsky, Todd L; Perini, Rodolfo F; He, Cixin Steven; Mody, Kalgi; Cella, David Journal: Lancet oncology Issue: Volume 23:Issue 6(2022) Page Start: 768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗